Research ExplorerPublicationsCorrigendum to "Initial experience with CDK4/6 inhibitor-bas...

Corrigendum to "Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany"

Standard

Corrigendum to "Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany". / Schneeweiss, Andreas; Ettl, Johannes; Lüftner, Diana; Beckmann, Matthias W; Belleville, Erik; Fasching, Peter A; Fehm, Tanja N; Geberth, Matthias; Häberle, Lothar; Hadji, Peyman; Hartkopf, Andreas D; Hielscher, Carsten; Huober, Jens; Ruckhäberle, Eugen; Janni, Wolfgang; Kolberg, Hans Christian; Kurbacher, Christian M; Klein, Evelyn; Lux, Michael P; Müller, Volkmar; Nabieva, Naiba; Overkamp, Friedrich; Tesch, Hans; Laakmann, Elena; Taran, Florin-Andrei; Seitz, Julia; Thomssen, Christoph; Untch, Michael; Wimberger, Pauline; Wuerstlein, Rachel; Volz, Bernhard; Wallwiener, Diethelm; Wallwiener, Markus; Brucker, Sara Y.

In: BREAST, Vol. 55, 02.2021, p. 138-139.

Research output: SCORING: Contribution to journal › Other (editorial matter etc.) › Research

Harvard

Schneeweiss, A, Ettl, J, Lüftner, D, Beckmann, MW, Belleville, E, Fasching, PA, Fehm, TN, Geberth, M, Häberle, L, Hadji, P, Hartkopf, AD, Hielscher, C, Huober, J, Ruckhäberle, E, Janni, W, Kolberg, HC, Kurbacher, CM, Klein, E, Lux, MP, Müller, V, Nabieva, N, Overkamp, F, Tesch, H, Laakmann, E, Taran, F-A, Seitz, J, Thomssen, C, Untch, M, Wimberger, P, Wuerstlein, R, Volz, B, Wallwiener, D, Wallwiener, M & Brucker, SY 2021, 'Corrigendum to "Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany"', BREAST, vol. 55, pp. 138-139. https://doi.org/10.1016/j.breast.2020.12.007

APA

Schneeweiss, A., Ettl, J., Lüftner, D., Beckmann, M. W., Belleville, E., Fasching, P. A., Fehm, T. N., Geberth, M., Häberle, L., Hadji, P., Hartkopf, A. D., Hielscher, C., Huober, J., Ruckhäberle, E., Janni, W., Kolberg, H. C., Kurbacher, C. M., Klein, E., Lux, M. P., ... Brucker, S. Y. (2021). Corrigendum to "Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany". BREAST, 55, 138-139. https://doi.org/10.1016/j.breast.2020.12.007

Vancouver

Schneeweiss A, Ettl J, Lüftner D, Beckmann MW, Belleville E, Fasching PA et al. Corrigendum to "Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany". BREAST. 2021 Feb;55:138-139. https://doi.org/10.1016/j.breast.2020.12.007

Bibtex

@article{c56e21f32bc84b4592fbf9f2eceead6e,
title = "Corrigendum to {"}Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany{"}",
author = "Andreas Schneeweiss and Johannes Ettl and Diana L{\"u}ftner and Beckmann, {Matthias W} and Erik Belleville and Fasching, {Peter A} and Fehm, {Tanja N} and Matthias Geberth and Lothar H{\"a}berle and Peyman Hadji and Hartkopf, {Andreas D} and Carsten Hielscher and Jens Huober and Eugen Ruckh{\"a}berle and Wolfgang Janni and Kolberg, {Hans Christian} and Kurbacher, {Christian M} and Evelyn Klein and Lux, {Michael P} and Volkmar M{\"u}ller and Naiba Nabieva and Friedrich Overkamp and Hans Tesch and Elena Laakmann and Florin-Andrei Taran and Julia Seitz and Christoph Thomssen and Michael Untch and Pauline Wimberger and Rachel Wuerstlein and Bernhard Volz and Diethelm Wallwiener and Markus Wallwiener and Brucker, {Sara Y}",
note = "Correction",
year = "2021",
month = feb,
doi = "10.1016/j.breast.2020.12.007",
language = "English",
volume = "55",
pages = "138--139",
journal = "BREAST",
issn = "0960-9776",
publisher = "Churchill Livingstone",

}

RIS

TY - JOUR

T1 - Corrigendum to "Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany"

AU - Schneeweiss, Andreas

AU - Ettl, Johannes

AU - Lüftner, Diana

AU - Beckmann, Matthias W

AU - Belleville, Erik

AU - Fasching, Peter A

AU - Fehm, Tanja N

AU - Geberth, Matthias

AU - Häberle, Lothar

AU - Hadji, Peyman

AU - Hartkopf, Andreas D

AU - Hielscher, Carsten

AU - Huober, Jens

AU - Ruckhäberle, Eugen

AU - Janni, Wolfgang

AU - Kolberg, Hans Christian

AU - Kurbacher, Christian M

AU - Klein, Evelyn

AU - Lux, Michael P

AU - Müller, Volkmar

AU - Nabieva, Naiba

AU - Overkamp, Friedrich

AU - Tesch, Hans

AU - Laakmann, Elena

AU - Taran, Florin-Andrei

AU - Seitz, Julia

AU - Thomssen, Christoph

AU - Untch, Michael

AU - Wimberger, Pauline

AU - Wuerstlein, Rachel

AU - Volz, Bernhard

AU - Wallwiener, Diethelm

AU - Wallwiener, Markus

AU - Brucker, Sara Y

N1 - Correction

PY - 2021/2

Y1 - 2021/2

U2 - 10.1016/j.breast.2020.12.007

DO - 10.1016/j.breast.2020.12.007

M3 - Other (editorial matter etc.)

C2 - 33413981

VL - 55

SP - 138

EP - 139

JO - BREAST

JF - BREAST

SN - 0960-9776

ER -